BRAF and neoplasm: Furthermore, the introduction of a first immunocompromised version of the AlbuMus allows accurate anti-tumour investigations of an anti-EGFR x anti-CD3 bispecific albumin fusion in BRAF-mutated tumours non-respondent to standard anti-EGFR monoclonal therapies.